HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,038,771 | +2.7% | 131,905 | -3.0% | 0.81% | +15.3% |
Q2 2023 | $4,905,268 | +46.0% | 135,993 | +54.6% | 0.70% | +38.3% |
Q1 2023 | $3,359,116 | -65.5% | 87,958 | -48.7% | 0.51% | -68.1% |
Q4 2022 | $9,748,336 | +43.0% | 171,324 | -0.7% | 1.60% | +36.3% |
Q3 2022 | $6,819,000 | – | 172,451 | – | 1.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |